Abstract:Guidelines suggest that adults with diabetes and kidney disease receive treatment with angiotensin‐converting‐enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). This is an update of a Cochrane review published in 2006. We compared the efficacy and safety of ACEi and ARB therapy (either as monotherapy or in combination) on cardiovascular and kidney outcomes in adults with diabetes and kidney disease. We searched the Cochrane Kidney and Transplants Register of Studies to 17 March 2024 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Registry Platform (ICTRP) Search Portal, and ClinicalTrials.gov. We included studies evaluating ACEi or ARB alone or in combination, compared to each other, placebo or no treatment in people with diabetes and kidney disease. Two authors independently assessed the risk of bias and extracted data. Summary estimates of effect were obtained using a random‐effects model, and results were expressed as risk ratios (RR) and their 95% confidence intervals (CI) for dichotomous outcomes and mean difference (MD) or standardised mean difference (SMD) and 95% CI for continuous outcomes. Confidence in the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. One hundred and nine studies (28,341 randomised participants) were eligible for inclusion. Overall, the risk of bias was high. Compared to placebo or no treatment, ACEi may make little or no difference to all‐cause death (24 studies, 7413 participants: RR 0.91, 95% CI 0.73 to 1.15; I 2 = 23%; low certainty) and with similar withdrawals from treatment (7 studies, 5306 participants: RR 1.03, 95% CI 0.90 to 1.19; I 2 = 0%; low certainty). ACEi may prevent kidney failure (8 studies, 6643 participants: RR 0.61, 95% CI 0.39 to 0.94; I 2 = 0%; low certainty). Compared to placebo or no treatment, ARB may make little or no difference to all‐cause death (11 studies, 4260 participants: RR 0.99, 95% CI 0.85 to 1.16; I 2 = 0%; low certainty). ARB have uncertain effects on withdrawal from treatment (3 studies, 721 participants: RR 0.85, 95% CI 0.58 to 1.26; I 2 = 2%; low certainty) and cardiovascular death (6 studies, 878 participants: RR 3.36, 95% CI 0.93 to 12.07; low certainty). ARB may prevent kidney failure (3 studies, 3227 participants: RR 0.82, 95% CI 0.72 to 0.94; I 2 = 0%; low certainty), doubling of serum creatinine (SCr) (4 studies, 3280 participants: RR 0.84, 95% CI 0.72 to 0.97; I 2 = 32%; low certainty), and the progression from microalbuminuria to microalbuminuria (5 studies, 815 participants: RR 0.44, 95% CI 0.23 to 0.85; I 2 = 74%; low certainty). Compared to ACEi, ARB had uncertain effects on all‐cause death (15 studies, 1739 participants: RR 1.13, 95% CI 0.68 to 1.88; I 2 = 0%; low certainty), withdrawal from treatment (6 studies, 612 participants: RR 0.91, 95% CI 0.65 to 1.28; I 2 = 0%; low certainty), cardiovascular death (13 studies, 1606 participants: RR 1.15, 95% CI 0.45 to 2.98; I 2 = 0%; low certainty), kidney failure (3 studies, 837 participants: RR 0.56, 95% CI 0.29 to 1.07; I 2 = 0%; low certainty), and doubling of SCr (2 studies, 767 participants: RR 0.88, 95% CI 0.52 to 1.48; I 2 = 0%; low certainty). Compared to ACEi plus ARB, ACEi alone has uncertain effects on all‐cause death (6 studies, 1166 participants: RR 1.08, 95% CI 0.49 to 2.40; I 2 = 20%; low certainty), withdrawal from treatment (2 studies, 172 participants: RR 0.78, 95% CI 0.33 to 1.86; I 2 = 0%; low certainty), cardiovascular death (4 studies, 994 participants: RR 3.02, 95% CI 0.61 to 14.85; low certainty), kidney failure (3 studies, 880 participants: RR 1.36, 95% CI 0.79 to 2.32; I 2 = 0%; low certainty), and doubling of SCr (2 studies, 813 participants: RR 1.14, 95% CI 0.70 to 1.85; I 2 = 0%; low certainty). Compared to ACEi plus ARB, ARB alone has uncertain effects on all‐cause death (7 studies, 2607 participants: RR 1.02, 95% CI 0.76 to 1.37; I 2 = 0%; low certainty), withdrawn from treatment (3 studies, 1615 participants: RR 0.81, 95% CI 0.53 to 1.24; I 2 = 0%; low certainty), cardiovascular death (4 studies, 992 participants: RR 3.03, 95% CI 0.62 to 14.93; low certainty), kidney failure (4 studies, 2321 participants: RR 1.15, 95% CI 0.67 to 1.95; I 2 = 29%; low certainty), and doubling of SCr (3 studies, 2252 participants: RR 1.18, 95% CI 0.85 to 1.64; I 2 = 0%; low certainty). Comparative effects of different ACEi or ARB and low‐dose versus high‐dose ARB were rarely evaluated. No study compared different doses of ACEi. Adverse -Abstract Truncated-

Is ramipril the pril for diabetes and kidney disease?

Ramipril blunts glycerol-induced acute renal failure in rats through its antiapoptosis, anti-inflammatory, antioxidant, and renin-inhibiting properties

Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease

Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial

P2643Antiproteinuric efficacy of ACE inhibitors, selective MRAs and ACE inhibitor/selective MRA combination therapy in diabetic hypertensives with microalbuminuria

Perindopril attenuates renal tubulointerstitium injury by inhibiting scavenger receptor A over-expression in diabetic rats

Prevention of Type 2 Diabetes Mellitus Through Inhibition of the Renin-Angiotensin System

Ramipril, an Angiotensin-Converting Enzyme Inhibitor, Ameliorates Oxidative Stress, Inflammation, and Hepatic Fibrosis in Alloxan-Induced Diabetic Rats

The effect of renin–angiotensin–aldosterone system inhibitors on continuous and binary kidney outcomes in subgroups of patients with diabetes: a meta-analysis of randomized clinical trials

Efficacy and Safety of Endothelin Receptor Antagonists in Type 2 Diabetic Kidney Disease: A Systematic Review and Meta‐analysis of Randomized Controlled Trials

Renal protection in diabetic patients: benefits of a first-line combination of perindopril-indapamide (Preterax)

Review: Potential protective effects of telmisartan on renal function deterioration

Novel effective drugs for diabetic kidney disease? or not?

Peritubular Capillary Loss is Ameliorated by Ramipril or Valsartan Treatment.

Benefit and risk evaluation of quinapril hydrochloride

[ACEi and ARBs: Proteinuria Containment and Nephroprotection]

Telmisartan: just an antihypertensive agent? A literature review

A Multicentre Study of the Safety of Ramiprill in High-Risk Cardiovascular Patients

Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency.

University of Miami Division of Clinical Pharmacology Therapeutic Rounds: managing hypertension in patients with kidney disease-implications for preservation of renal function

Effects of Angiotensin II Receptor Antagonist Olmesartan on Renal Hemodynamic Variables and Vascular Structural Properties in Streptozotocin-Induced Diabetic Rats